Moderna CFO out of job after two days

Jorge Gomez, who stepped into the role of CFO for Moderna May 9, is already out of a job.

The sudden departure was a result of an internal probe of financial reporting by Gomez’s former employer, Dentsply Sirona, American dental equipment manufacturer and dental consumables producer. Moderna is a Cambridge, Massachusetts-based pharmaceutical company and is one of three drug makers with approved COVID-19 vaccines in the U.S. Moderna announced Gomez left the job May 11.

Moderna cited “an ongoing internal investigation into certain matters” in its announcement. David Meline, who recently retired as CFO of Moderna, will resume the role, effective May 11, as the company searches for a replacement.

Dentsply Sirona announced it will be filing its Form 10-Q late as a result of the internal probe.

“The investigation is ongoing, and the company cannot predict the duration or outcome of the investigation,” stated an SEC filing from Dentsply Sirona. “As a result, the company has not yet finalized its financial statements or its assessment of the impact of the investigation on its historical financial statements or for the financial statements for the three months ended March 31, 2022, and is therefore unable to file the Form 10-Q on a timely basis.”

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

A string of executive orders from the White House created serious concerns among radiologists and other healthcare providers throughout the United States. The American College of Radiology issued a statement to help guide its members through the chaos. 

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.